Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teduglutide in Japanese Pediatric SBS
NCT02980666Phase 3Completed
- Sponsor
- Takeda
- Start
- Jan 2017
- Primary completion
- Jan 2020
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of teduglutide in short bowel syndrome (SBS), sponsored by Takeda. Primary endpoints: Absolute and Percent Change From Baseline in Parenteral Support (PS) Volume at Week 28, Absolute and Percent Change From Baseline in Parenteral Support (PS) Caloric Intake at Week 28 and 10 more. Started Jan 2017; status: completed.
02
Drugs
teduglutide
03
Conditions
short bowel syndrome (SBS)
Beyond the preview
Go deeper on NCT02980666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02980666.